Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 20 respiratory brands in the U.S. based on revenue in 2016 (in million U.S. dollars)

Exclusive Premium Statistic

Revenue of top 20 respiratory brands in the U.S. 2016 This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Show more
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Show more
Release date
April 2017
Region
United States
Survey time period
2016

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Asthma in the U.S."

  • Prevalence
The most important statistics
  • Asthma attacks
The most important statistics
  • Deaths
  • Regions and states
The most important statistics
  • Doctors and hospitals
The most important statistics
  • Medication
The most important statistics

Related Studies: Available to Download in PDF or PPTX Format

Asthma in the U.S.

All Information
in one Presentation

Asthma in the U.S.

Everything On "Asthma in the U.S." in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
2 News

We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.